What is the recommended docetaxel‑cisplatin‑5‑fluorouracil (DCF) induction chemotherapy regimen for an adult patient with locally advanced esophageal squamous cell carcinoma, clinical stage T3 N2?

DCF Induction Protocol for Locally Advanced Esophageal SCC (cT3N2)

For locally advanced esophageal squamous cell carcinoma cT3N2, preoperative chemoradiotherapy (CRT) is the guideline-recommended standard treatment, NOT induction DCF chemotherapy alone. 1

Guideline-Based Treatment Approach

The 2020 ASCO guidelines strongly recommend preoperative CRT or definitive CRT for locally advanced esophageal SCC 1. The standard approach is:

• Preferred regimen: Carboplatin/paclitaxel with concurrent radiation (CROSS regimen) followed by surgery
• Alternative: Cisplatin/5-FU with concurrent radiation

DCF is NOT mentioned as a standard induction regimen in current ASCO or ESMO guidelines for resectable esophageal SCC 1, 2. The guidelines specifically note that for SCC, preoperative chemotherapy without radiation may only be considered when radiation is not an option 1.

If DCF Induction is Being Considered (Off-Guideline)

Despite lack of guideline endorsement, if DCF induction is pursued based on emerging evidence, the established protocol from Japanese studies is:

Standard DCF Dosing (3-week cycles):

• Docetaxel: 70 mg/m² IV on day 1
• Cisplatin: 70 mg/m² IV on day 1
• 5-Fluorouracil: 750 mg/m²/day continuous infusion days 1-5
• Cycles: 2-3 cycles every 3 weeks 3, 4

Key Protocol Details:

• Mandatory antibiotic prophylaxis days 5-15 of each cycle 4
• Premedication: Dexamethasone 16 mg/day (8 mg BID) for 3 days starting 1 day before docetaxel 5
• Antiemetics and hydration required for cisplatin administration 5

Number of Cycles:

A randomized phase II trial showed 2 cycles may be sufficient, with comparable 2-year PFS (71.4% vs 71.1%) and better tolerability compared to 3 cycles 3. However, patients under 65 years showed a trend toward better survival with 3 cycles 3.

Modified Dosing Option:

Biweekly divided-dose DCF (Bi-DCF) has shown improved tolerability while maintaining dose intensity, with grade ≥3 adverse events in 44.4% vs higher rates with standard dosing 6. This may be appropriate for elderly or less fit patients.

Critical Caveats

1. This is investigational: DCF induction for resectable SCC is primarily studied in Japanese populations and is NOT standard-of-care per Western guidelines 1, 2

2. Expected toxicities: Grade 3-4 neutropenia occurs in 61-83% of patients, febrile neutropenia in 26.7% 4, 7. Non-hematologic toxicities include anorexia (7-9%), stomatitis (5%), and pulmonary embolism (8%) 4, 7

3. Treatment completion: Approximately 90% complete the protocol, with 9-11% discontinuing due to toxicity 4, 7

4. Subsequent treatment: After DCF, patients should proceed to either:

   • Surgery (if resectable with good response)
   • CRT followed by surgery (trimodality approach)
   • Definitive CRT (if surgery not feasible)

5. Pathological response: pCR rates of 14.7-17% have been reported 4, 7, which is lower than what is achieved with preoperative CRT

Recommended Clinical Approach

For your cT3N2 esophageal SCC patient, follow guideline-based treatment:

1. First-line recommendation: Preoperative CRT (carboplatin/paclitaxel + 41.4 Gy) followed by surgery 1, 2

2. If radiation contraindicated: Consider perioperative chemotherapy, though this is better established for adenocarcinoma 1

3. DCF induction should only be considered in the context of:

   • Clinical trial enrollment (e.g., JCOG1510 TRIANgLE trial) 8
   • Multidisciplinary discussion at high-volume centers with experience in this approach
   • Patient preference after informed consent about off-guideline use

The evidence for DCF induction in resectable SCC is promising but remains investigational and is not yet supported by phase III data or international guidelines.